Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Neurology
4
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

CSL Behring
CSL BehringIL - Bradley
1 program
1
IgPro20Phase 31 trial
Active Trials
NCT02027701Completed82Est. Jul 2017
Vera Therapeutics
Vera TherapeuticsBRISBANE, CA
1 program
1
Immune Globulin 10% Intravenous SolutionPhase 31 trial
Active Trials
NCT03166527UnknownEst. Dec 2018
argenx
argenxBelgium - Zwijnaarde
2 programs
2
Efgartigimod PH20 SCPhase 21 trial
efgartigimod PH20 SC in stage BPhase 21 trial
Active Trials
NCT04280718Active Not Recruiting229Est. Apr 2027
NCT04281472Completed322Est. May 2023
UP
UCB PharmaBelgium - Brussels
1 program
RozanolixizumabN/AMonoclonal Antibody1 trial
Active Trials
NCT05014724No Longer Available

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Vera TherapeuticsImmune Globulin 10% Intravenous Solution
CSL BehringIgPro20
argenxEfgartigimod PH20 SC
argenxefgartigimod PH20 SC in stage B

Clinical Trials (5)

Total enrollment: 633 patients across 5 trials

NCT03166527Vera TherapeuticsImmune Globulin 10% Intravenous Solution

Panzyga in CIDP Administered at Different Infusion Rates

Start: Jun 2017Est. completion: Dec 2018
Phase 3Unknown
NCT02027701CSL BehringIgPro20

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Start: Jul 2014Est. completion: Jul 201782 patients
Phase 3Completed
NCT04280718argenxEfgartigimod PH20 SC

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Start: Sep 2020Est. completion: Apr 2027229 patients
Phase 2Active Not Recruiting
NCT04281472argenxefgartigimod PH20 SC in stage B

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Start: Apr 2020Est. completion: May 2023322 patients
Phase 2Completed
NCT05014724UCB PharmaRozanolixizumab

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

N/ANo Longer Available

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)